AFFiRiS: Milestone Reached in Clinical Trial of Alzheimer...(r MIG-Fonds is crucialin this regard as ...),Health

The Alzheimer's vaccines developed by AFFiRiS are based on AFFITOME technology developed in-house, which functions using the mimotope principle. This technology enables the development of customized vaccines known as AFFITOPE. Dr. Schmidt explains the special features of AFFiRiS's approach to the Alzheimer's vaccine: "Alzheimer's is caused by beta-amyloid, an unwanted fragment of one of the body's own proteins that occurs on the surface of brain cells. Development of a successful vaccine is extremely challenging as it is vital to ensure that antibodies only attack beta-amyloid if it occurs separated in the brain fluid but not as long as it is still part of the normal APP protein on the brain cells. The brain cells would otherwise be attacked. Thanks to AFFITOME technology, we are in the unique position of being able to safely protect the brain cells and only combat the disease-causing beta-amyloid."

AFFITOME technology patented by the company enables scientists to create both molecules with very specific binding characteristics and molecules that differ in structure but exhibit identical binding characteristics. These strengths are now being used in developing the AD01 and AD02 vaccines, both of which align the immune system against the same beta-amyloid structure. However, AFFITOME technology can also be used to have a positive influence on other human rogue proteins - such as lipid metabolism enzymes. Consequently, an appropriate development by AFFiRiS could provide an effective treatment for atherosclerosis.

Michael Motschmann, Senior Fund Manager at MIG-Fonds, explains his views on this development by AFFiRiS GmbH: "The company specialises in the development of treatments for diseases that urgently require a medical solution and also offer attractive market potential. With 22 million sufferers predicted for 2025 and no effect
'/>"/>